The BALI consortium performs multidisciplinary research to design Synthetic Antimicrobial Antibiofilm Peptides (SAAP) and a release system which can be applied to the surface of biomaterials as a coating. We aim to develop novel SAAPs with optimized in vitro antimicrobial, anti-inflammatory and biofilm-dispersing activity (WP2) and to investigate their mode of action (WP3). An innovative delivery formulation (PolyPid platform) will be used to allow prolonged and pre-determined release rates of the most promising SAAPs (WP4).
This platform ensures local delivery of effective concentrations of the peptide over a sufficient duration and can be developed into coatings for different types of implants. To obtain in vivo proof of concept, the efficacy to prevent and treat biomaterial-associated infections of PolyPid/SAAP-coated polymer and titanium implants will be tested in various clinically relevant in vivo model systems (WP5 and WP6). The most promising SAAP will be produced under GMP conditions and the PolyPid/SAAP coating will be evaluated in a first human Phase I clinical trial to study the safety and efficacy of coated intramedullary nails (WP7). Results will be actively disseminated to specialized and general audiences (WP8).
Infection related to inserted or implanted medical devices (“biomaterials”) is a major problem. These infections are often caused by aggregates of microorganisms embedded within a self-produced matrix of extracellular substance adhering to biomaterials (biofilms) and by bacteria surviving in tissue surrounding the implanted biomaterial. Biofilms are notoriously resistant to antibiotics and there currently is no effective strategy to control biofilm formation. Similarly, bacteria in the surrounding tissue are difficult to target, partly because they may be localized within host cells. As a result biomaterial-associated infections cannot be prevented or adequately treated.
The BALI consortium aims to develop novel tools to control biofilms by targeting both the prevention and treatment of biomaterial-associated infections. This will be achieved by the unique combination of two highly innovative technologies; Synthetic Antimicrobial Antibiofilm Peptides (SAAP) and a PolyPid release system, which can be applied to the surface of biomaterials as a coating.
Design of SAAPs with optimized antimicrobial and biofilm-dispersing activity and elucidation of their mode of action. An innovative delivery formulation will be used to allow controlled release of the most promising SAAPs from biomaterial surfaces. Efficacy of PolyPid/SAAP-coated biomaterials will be studied in in vivo model systems, and a phase I clinical trial will be performed to assess safety, and possibly efficacy, to prevent biomaterial infections.
Prevention and treatment of biomaterial-associated infections by controlled release of SAAPs from biomaterial coatings.